Get started

Stockstobuy

NYKAATechnical Data 1.Accumulation Phase of About 1 Year 2.Increased Volume during Accumulation Phase 3.Big Breakout on Weekly TF with Big Volume 4. Retest of This phase is also done 5. Price Respected Breakout zone of 150-155 6. Rejection & Buying Confirmed on Weekly TF Fundamental Data Analysis 1.Company is posting Increased Quarterly Results 2.Fundamentals & Company management is strong 3.Big Institutions also increasing stakes continuously 4. Kind of monopoly listed player in Market (Study BSE for monopoly listed player) 5. Consistently growing business & market share Buy at CMP @155-157 SL- @135 Target 1-310 (100% Returns) Target 2 - 410 (More than 150%) Time Period- Next 6-12 Months
NSE:NYKAALong
by Wealthy_Vikish
1
LSXMA - Good Upside PotentialLSXMA broke the parallel channel that was holding the price since November 2022 after making a double bottom with the March 2020 low, I also liked the fact that the 2D SMMA was also broken, after having served as resistance since January 2023 and it is currently retesting it, and as if that wasn't enough to be bullish, LSXMA had a bullish divergence on the RSI on the weekly time frame. I believe that if the LSXMA price holds above the parallel channel (SMMA), it could be the beginning of a new up trend, and could give good gains in the medium term.
LLong
by The_Trading_Wizard_
MPW's $4.60 Price Target After Bullish BreakoutTechnical Analysis MPW has been showing some solid bullishness out of the buy zone. There has been 6 consecutive green weekly candles so far including this week. MPW is forming a bullish breakout above this light blue trendline and orange resistance zone. I think there will be a pullback at some point, but for now the trend is still bullish and $4.60 is the key price target on this move up. Medical Properties Trust (MPW): Navigating Liquidity And Strategic Asset Management Medical Properties Trust Inc. (NYSE: MPW) recently shared insights into its financial health and strategic direction during its fourth quarter 2023 earnings call. With a focus on creating significant liquidity and managing its diverse portfolio of healthcare facilities, the company outlined its plan to navigate through current challenges and capitalize on its strengths. This blog delves into the key takeaways from the earnings call, highlighting both the bullish and bearish aspects of MPW’s strategy and performance. Strategic Initiatives For Enhanced Liquidity MPW’s CEO, Edward Aldag Jr., unveiled a capital allocation strategy aimed at generating at least $2 billion in liquidity by 2024. This ambitious plan involves the sale of Australian facilities and hospitals to Prime Healthcare Services, showcasing MPW’s proactive approach to capital management. These strategic asset sales, alongside ongoing opportunities, underscore the company’s commitment to financial flexibility and growth. Addressing Challenges With Optimism Despite facing issues with Steward Health Care System’s cash collections, MPW remains optimistic. The company is actively working on re-tenanting Steward properties, reflecting confidence in its ability to manage tenant-related challenges effectively. Additionally, the improved performance of Prospect Medical Holdings adds a layer of positivity, reinforcing MPW’s diversified portfolio’s strength. A Look At The Bearish And Bullish Highlights Bearish Insights: The distressed situation with Steward has necessitated strategic re-tenanting and asset sales to ensure consistent rent payments. A significant write-down of $90 million for loans to Steward underscores the financial challenges faced. Concerns remain for an operator within the cash accounting pool, projecting no financial support due to low coverage. Bullish Perspectives: Interest from multiple potential tenants for Steward properties indicates robust demand for MPW’s assets. The company’s European and American portfolios, including Circle Health and Priory, demonstrate strong performance. Prospect Medical Holdings’ turnaround contributes to the positive outlook, highlighting potential for growth. Future Outlook And InvestingPro Insights Looking ahead, MPW is poised to achieve its strategic objectives, bolstered by a focus on sustaining community health through acute care hospitals. The company’s strategic sales and financing plans aim to navigate the complex financial landscape successfully. From an investment perspective, MPW presents a mixed bag of opportunities and challenges. According to InvestingPro data, the company boasts a market cap of $2.28 billion USD and an appealing dividend yield of 15.79%. The aggressive share buyback program and low Price / Book multiple suggest that MPW may be undervalued, offering potential for income generation and price appreciation. Conclusion Medical Properties Trust Inc. is at a pivotal point, with strategic initiatives in place to enhance liquidity and manage its portfolio effectively. While challenges remain, particularly with certain tenants, the company’s optimistic approach and strategic sales indicate a forward-looking perspective. For investors, MPW’s current valuation and dividend yield may offer attractive opportunities, especially for those focused on income generation and value investing. As MPW navigates its strategic path, its ability to adapt and capitalize on its strengths will be crucial in driving future success.
NYSE:MPWLong
by realchartchamp
NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up. Novavax Reaches Settlement With Gavi, Paving The Way Forward In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations. The Dispute Resolution Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022. Impact On Novavax The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs. Settlement Terms Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark. Strategic Implications For Novavax The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company. Looking Ahead With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities. Conclusion In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
NASDAQ:NVAXLong
by realchartchamp
Suryoday Small Fin Bank - Swing and Mid Term Investment PickThe stock is in up trend in Monthly , weekly. The Weekly and Monthly RSI are fantastic, just moving above 60 on the way after touching the lower band at 40. The weekly has given a multi year breakout, has just broken the supply range at 190. I would consider an entry at 188 zone - Retest and look for 225 as swing trade target . 25 % For an Investment, I would consider a 1:2 Risk reward , SL at 145 level - weekly closing basis, Target at 280. I consider trailing my investment profits at each level with an exit if closing below 20% from any level.
NSE:SURYODAYLong
by Rugminik
EMAMI LTD SWING TRADE FOR COMING 3-6 MONTHS1.Bullish Chart Pattern is Forming on Higher TF of Weekly & Monthly 2. Kind Of H&S Pattern is getting structured 3. Currently Trading at Monthly Demand Zone of 450-460 4. Filled a gap on Daily TF 5. Bullish Engulfing on Daily TF with Heavy Volume 6. Fundamentals and company business is intact and showing growth consistently with Profits 7. Share Holding Pattern is also strong among big players & Institutions. Buy @ 460-465 Stop Loss - 445 Target- 1st- 600 2nd- 700 & 3rd & Final- 900 View Holding For Next 3-9 Months
NSE:EMAMILTDLong
by Wealthy_Vikish
3